Education
About Us
Working with TipRanks
Follow Us
Eyepoint Pharma (EYPT)
NASDAQ:EYPT
EYPT Stock Chart & Stats
$14.07
$0.01(0.11%)
At close: 4:00 PM EST
$14.07
$0.01(0.11%)
Day’s Range― - ―
52-Week Range$3.91 - $19.11
Previous CloseN/A
Volume354.62K
Average Volume (3M)960.90K
Market Cap
$1.14B
Enterprise Value$1.01B
Total Cash (Recent Filing)$204.02M
Total Debt (Recent Filing)$21.30M
Price to Earnings (P/E)―
Beta1.73
Next Earnings
Mar 05, 2026EPS Estimate
-0.75Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.85
Shares Outstanding82,787,220
10 Day Avg. Volume1,187,482
30 Day Avg. Volume960,897
Financial Highlights & Ratios
PEG Ratio-0.12
Price to Book (P/B)1.25
Price to Sales (P/S)9.69
P/FCF Ratio-3.22
Enterprise Value/Market Cap0.89
Enterprise Value/Revenue23.96
Enterprise Value/Gross Profit25.46
Enterprise Value/Ebitda-4.83
Forecast
1Y Price Target
$33.80Price Target Upside140.23% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-2.91
Revenue Forecast (FY)$10.77M
Bulls Say, Bears Say
Bulls Say
Pipeline ExpansionAdvancing a Phase 3 program in diabetic macular edema based on positive earlier data expands DURAVYU's potential market beyond wet AMD, creating additional avenues for commercial upside.
Regulatory PathwayFDA guidance suggesting a single robust Phase 3 trial could support approval for tyrosine kinase inhibitors may shorten the approval pathway for DURAVYU, improving the probability of regulatory success.
Safety MonitoringConsecutive recommendations from an independent Data Safety Monitoring Committee to continue both Phase 3 trials without protocol changes support an acceptable safety profile for DURAVYU, lowering development uncertainty.
Bears Say
Clinical Outcome RiskFailure of DURAVYU to meet primary endpoints in Phase 3 or inability to secure regulatory approval would materially undermine value and impede future commercialization plans.
Commercial And Payer HeadwindsStrong competition from established intravitreal therapies and potential payer resistance to higher-cost durable treatments could limit market penetration and slow revenue adoption.
Market Access DisruptionA lapse in external funding that increases use of low-cost alternatives like Avastin can reduce reimbursement willingness and create access barriers for new, higher-priced therapies.
EYPT FAQ
What was Eyepoint Pharma’s price range in the past 12 months?
Eyepoint Pharma lowest stock price was $3.91 and its highest was $19.11 in the past 12 months.
What is Eyepoint Pharma’s market cap?
Eyepoint Pharma’s market cap is $1.14B.
When is Eyepoint Pharma’s upcoming earnings report date?
Eyepoint Pharma’s upcoming earnings report date is Mar 05, 2026 which is in 21 days.
How were Eyepoint Pharma’s earnings last quarter?
Eyepoint Pharma released its earnings results on Nov 05, 2025. The company reported -$0.85 earnings per share for the quarter, missing the consensus estimate of -$0.769 by -$0.081.
Is Eyepoint Pharma overvalued?
According to Wall Street analysts Eyepoint Pharma’s price is currently Undervalued.
Does Eyepoint Pharma pay dividends?
Eyepoint Pharma does not currently pay dividends.
What is Eyepoint Pharma’s EPS estimate?
Eyepoint Pharma’s EPS estimate is -0.75.
How many shares outstanding does Eyepoint Pharma have?
Eyepoint Pharma has 82,787,220 shares outstanding.
What happened to Eyepoint Pharma’s price movement after its last earnings report?
Eyepoint Pharma reported an EPS of -$0.85 in its last earnings report, missing expectations of -$0.769. Following the earnings report the stock price went down -11.057%.
Which hedge fund is a major shareholder of Eyepoint Pharma?
Currently, no hedge funds are holding shares in EYPT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
EyePoint Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$33.80 (140.23% Upside)
$33.80 (140.23% Upside)
Blogger Sentiment
Bullish
EYPT Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 445.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.5%
Last 30 Days ▼ 0.2%
Last 30 Days ▼ 0.2%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
116.62%
12-Months-Change
Fundamentals
Return on Equity
-98.23%
Trailing 12-Months
Asset Growth
-16.36%
Trailing 12-Months
Company Description
Eyepoint Pharma
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.
EYPT Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
EyePoint demonstrated strong clinical progress with successful trial enrollments and maintained a robust financial position to support future operations. However, the company faced challenges with decreased revenue and increased operating expenses leading to a higher net loss. Despite financial setbacks, the strategic advancements in clinical programs and regulatory alignments position EyePoint for continued growth and potential market leadership.View all EYPT earnings summariesEYPT Stock 12 Month Forecast
Average Price Target
$33.80
▲(140.23% Upside)
Technical Analysis
Urogen Pharma
―
Meiragtx Holdings
―
Stoke Therapeutics
―
Tango Therapeutics
―
Pharming Group
―
Ownership Overview
10.89% Insiders
16.43% Mutual Funds
0.16% Other Institutional Investors
61.37% Public Companies and
Individual Investors